CLOV
Clover Health Investments, Corp. · Healthcare · Medical - Healthcare Plans
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +23.0% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 85 | +6 | 128.61M | $672.46M | +12 | −6 |
| Q1 2026 | 82 | +5 | 113.55M | $200.08M | +10 | −5 |
| Q4 2025 | 76 | -1 | 119.92M | $281.85M | — | −1 |
| Q3 2025 | 14 | -2 | 85.90M | $262.85M | — | −2 |
| Q2 2025 | 13 | +1 | 91.13M | $254.25M | +1 | — |
| Q1 2025 | 9 | 0 | 31.30M | $112.39M | +2 | −2 |
| Q4 2024 | 9 | 0 | 25.46M | $80.20M | — | — |
| Q3 2024 | 8 | +1 | 20.89M | $58.90M | +2 | −1 |
| Q2 2024 | 7 | — | 19.27M | $23.70M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies ✦ | 11.02M | -0.4% | $39.58M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 2 | Millennium Management ✦ | 5.80M | +365.9% | $20.84M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 5.03M | +3.0% | $18.07M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 5.03M | +3.0% | $18.07M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Marshall Wace ✦ | 4.58M | +21.4% | $16.43M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Marshall Wace ✦ | 4.58M | +21.4% | $16.43M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Marshall Wace ✦ | 4.58M | +21.4% | $16.43M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | State Street Global Advisors ✦ (passive) | 2.93M | +4.6% | $10.51M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 1.73M | +90.3% | $6.23M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 1.73M | +90.3% | $6.23M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 152.50K | New | $548,000 | 0.0% | New | 1 | SEC ↗ |
| 12 | Gotham Asset Management ✦ | 40.93K | -4.7% | $146,928 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 13.58K | New | $48,738 | 0.0% | New | 1 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 13.58K | New | $48,738 | 0.0% | New | 1 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 13.58K | New | $48,738 | 0.0% | New | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 13.58K | New | $48,738 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| T. Rowe Price | $548,000 | 0.0% |
| AQR Capital Management | $48,738 | 0.0% |
| AQR Capital Management | $48,738 | 0.0% |
| AQR Capital Management | $48,738 | 0.0% |
| AQR Capital Management | $48,738 | 0.0% |
Exited
| Two Sigma Investments | $1.59M | was 0.0% |
| Point72 Asset Management | $747,180 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 207 holders, 127.13M shares, $218.62M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 17.77K sh · $78,032
Officer, Director · 87.80K sh · $408,261
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology